<DOC>
	<DOCNO>NCT00961766</DOCNO>
	<brief_summary>The primary objective study determine safety/tolerability profile , systemic PK behavior , immunogenicity single IV SC administration BG00010 sciatica participant .</brief_summary>
	<brief_title>Evaluate Safety , Tolerability Pharmacokinetics BG00010 ( Neublastin ) Administered Sciatica Participants</brief_title>
	<detailed_description />
	<mesh_term>Sciatica</mesh_term>
	<criteria>Key Must diagnosis unilateral sciatica , determine Investigator . Sciatica symptom must present 6 week prior Screening Visit . Must body mass index ( BMI ) 18 kg/m2 32 kg/m2 . Must rate pain &gt; 40 mm 100 mm Visual Analog Scale ( VAS ) ShortForm McGill Pain Questionnaire ( SFMPQ ) Screening Baseline Visits . Key History malignancy clinically significant ( determined Investigator ) allergy , cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic ( related sciatica ) , dermatologic , rheumatic/joint , psychiatric , renal , and/or major disease . History sign symptoms peripheral neuropathy , symptom sciatica . History severe allergic anaphylactic drugrelated reaction . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>